Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT00836771Not ApplicableUnknown

Infant Formula Supplemented With Probiotic Microorganisms and/or Prebiotic.

Role: lead

NCT01140243Not ApplicableCompleted

Infant Formula Supplemented With a Special Fat Formulation for Premature Infants Following Discharge From Hospital

Role: lead

NCT00292812Not ApplicableCompleted

Clinical Effects of a Nucleotides-Supplemented Infant Formula

Role: collaborator

All 3 trials loaded